CJC-1295 vs ipamorelin: how the two peptides differ

Last updated 2026-07-26

What is the actual difference between CJC-1295 and ipamorelin?

CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH). It binds the GHRH receptor on pituitary somatotroph cells and tells them to release growth hormone, essentially amplifying the body's own signal. Ipamorelin is a different class entirely: it's a pentapeptide that acts as a ghrelin receptor agonist, also called a growth hormone secretagogue (GHS). It mimics ghrelin's action at the GHS-R1a receptor to stimulate GH release through a separate pathway. The distinction matters because GH release in the body is normally controlled by two counterbalancing signals: GHRH (which pushes GH release) and somatostatin (which suppresses it). Ghrelin-mimetic compounds like ipamorelin work partly by blunting somatostatin's brake, while GHRH analogues like CJC-1295 work by boosting the accelerator. Combine a compound that removes the brake with one that presses the gas, and in theory you get a bigger, cleaner pulse than either alone. That's the mechanistic argument, not a trial result. Ipamorelin was first characterized in the peer-reviewed literature by Raun et al., who described it as having a GH-releasing profile 'similar to that of GHRP-6 but with a more selective mode of action, since ipamorelin did not release ACTH, cortisol or prolactin' in the animal models tested ^[1]. That selectivity is the main reason ipamorelin displaced older secretagogues like GHRP-6 in research use: less cortisol and prolactin spillover means a cleaner GH signal without some of the side effects tied to older peptides. For a side-by-side on the DAC question specifically, see CJC-1295 DAC or no DAC.

CJC-1295 vs ipamorelin: quick comparison table

How does CJC-1295 work in the body?

CJC-1295 is built on the structure of GHRH(1-29), the biologically active fragment of natural growth hormone releasing hormone, with amino acid substitutions designed to resist enzymatic breakdown. The original modifications were described in the pharmacology literature as producing a GHRH analogue with 'markedly enhanced potency and duration of action' compared to native GHRH ^[2]. The DAC version attaches a Drug Affinity Complex, a maleimide linker that lets the peptide bind covalently to albumin in the bloodstream once injected. Because albumin has a long circulating half-life, the peptide gets a free ride and persists far longer than it would alone. Teichman et al., in a study of CJC-1295 with DAC in healthy adults, reported that a single dose produced 'sustained increases in GH and IGF-I levels for 6 days or longer' ^[2]. That is the entire basis for CJC-1295's reputation as a 'long-acting' GHRH analogue: one real pharmacokinetic study in humans, not decades of trials. The no-DAC version (sometimes called CJC-1295 without DAC, or confusingly mislabeled 'mod GRF 1-29' in gray-market circles) lacks that albumin-binding tail. Its half-life is short, in the range of 30 minutes, closer to native GHRH's kinetics ^[2]. That short half-life is why no-DAC dosing protocols tend to mimic the body's natural pulsatile GH release, meaning multiple small daily doses rather than one weekly injection. For practical handling once you have either form, see CJC-1295 reconstitution and CJC-1295 storage and shelf life, since both forms are supplied as lyophilized powder and degrade quickly if mishandled.

How does ipamorelin work in the body?

Ipamorelin is a pentapeptide, meaning it has five amino acids, and is structurally in the same family as older growth hormone releasing peptides (GHRP-2, GHRP-6, hexarelin) but with a narrower pharmacological footprint. It binds the ghrelin receptor (GHS-R1a) on the pituitary and hypothalamus, and that binding triggers GH release largely independent of, but additive with, GHRH signaling. The defining feature reported in the founding study is selectivity. Raun and colleagues tested ipamorelin against other GH secretagogues in rats and found it stimulated GH release 'dose-dependently' while other compounds in the same class caused meaningful ACTH and cortisol release; ipamorelin largely did not ^[1]. That's the practical reason people reach for ipamorelin over GHRP-6 or GHRP-2: theoretically less cortisol and prolactin noise for a similar GH signal, at least in the animal data available. Human pharmacokinetic data on ipamorelin is thinner than people assume. Most of what's cited in secondary sources traces back to early pharma-industry pharmacology work (ipamorelin was originally developed by Novo Nordisk, later licensed out) rather than large peer-reviewed human trials. A commonly cited elimination half-life of around 2 hours in humans appears in pharmacological reviews of GH secretagogues ^[3], but there isn't a large modern clinical trial establishing dose-response curves the way there is for approved GH-axis drugs.

Why are CJC-1295 and ipamorelin used together?

The stacking rationale is mechanistic, not clinical. GHRH analogues and ghrelin-receptor agonists act on different receptors and different points in the GH-regulation feedback loop, so combining them is meant to produce a larger, more synchronized GH pulse than either compound alone. That idea has real pharmacological logic behind it. GHRH increases GH synthesis and release capacity; ghrelin-mimetics like ipamorelin reduce somatostatin's inhibitory tone at the same time. Push the accelerator and release the brake together, and the pulse should, in theory, be bigger. This combination logic is well established for other GHRH/GHS pairs in the endocrinology literature generally, and it's the same logic underlying combination protocols in some clinical GH-stimulation testing contexts. But 'the mechanism supports combining them' is different from 'a trial has shown the combination produces superior outcomes to either alone in humans using these specific compounds.' No large randomized trial of CJC-1295 plus ipamorelin, at any dose, in any population, has been published in a flagship peer-reviewed journal as of this writing. What exists is: pharmacokinetic work on each compound separately, animal data on ipamorelin's selectivity, and one human PK study on CJC-1295 with DAC. The rest of the 'combined effect' claims that circulate come from anecdotal forum reporting, not controlled trials. Be honest with yourself about what that means. If you're combining them, you're combining two compounds whose individual pharmacology is reasonably well characterized, on a mechanistic bet that hasn't been tested head-to-head against monotherapy in a controlled human study. That's a legitimate hypothesis. It is not settled science.

Is CJC-1295 or ipamorelin better for muscle growth or fat loss?

Neither has approved-drug-level evidence for muscle growth or fat loss in healthy adults, so 'better' is the wrong frame. What's actually documented is that GH and IGF-I elevation (which both compounds are designed to produce) is associated with anabolic and lipolytic effects in the broader endocrinology literature on growth hormone physiology, largely from studies of GH deficiency treatment and GH replacement, not from studies of these specific research peptides in healthy people trying to build muscle. The closest real regulatory analog is tesamorelin, a GHRH analogue related in class to CJC-1295, which the FDA approved specifically for reduction of excess visceral fat in HIV-associated lipodystrophy ^[4]. That approval exists because tesamorelin went through actual Phase 3 trials for that narrow indication. CJC-1295 has not been through that process for any indication, and neither has ipamorelin. Extrapolating tesamorelin's approved effect to CJC-1295's presumed effect is reasonable pharmacology but is still extrapolation, not direct proof. Bodybuilding forums are the dominant source of claims that either peptide, alone or stacked, drives visible fat loss or lean mass gain in healthy non-deficient adults. That's lore, not evidence. It might turn out to be roughly true given the mechanism, but nobody has published the controlled trial that would confirm it, and dose, duration, and population all matter enormously in how GH axis stimulation plays out.

How do the dosing schedules differ between CJC-1295 and ipamorelin?

CJC-1295 with DAC is engineered for infrequency, since its whole design goal is a long albumin-bound half-life. The Teichman study measured sustained GH and IGF-I elevation for 6 days or more after a single dose ^[2], which is the pharmacokinetic basis for once-weekly dosing schedules used in research and gray-market protocols. CJC-1295 without DAC has a half-life closer to 30 minutes, so protocols built around it usually call for once or twice daily dosing, often timed to overnight or pre-workout windows to align with the body's natural GH pulsing. Ipamorelin's short half-life (roughly 2 hours per pharmacological reviews of GH secretagogues ^[3]) drives a similar multi-dose logic: most protocols use it once to three times daily, frequently timed around fasting states (morning, pre-bed, post-workout) because GH secretagogues are generally understood to work better with low circulating insulin and glucose. When the two are combined, the pairing usually follows CJC-1295's schedule as the backbone (daily or weekly depending on DAC status) with ipamorelin layered in at its own more frequent cadence. None of this is FDA-labeled dosing; it's protocol convention drawn from the individual compounds' pharmacokinetics, and it varies a fair amount across sources with no controlling authority reconciling it.

What are the side effects of CJC-1295 compared to ipamorelin?

Because both compounds act upstream of actual GH release, most reported side effects mirror generic GH-axis stimulation: water retention, joint or extremity puffiness, transient flushing at higher doses, and injection-site reactions. Neither compound has an FDA-reviewed adverse event profile because neither is an approved drug in the US; what's cited in most secondary sources traces back to the same handful of early pharmacology studies. CJC-1295's DAC version carries an added consideration: because it stays bound to albumin and keeps GH/IGF-I elevated for days, any side effect tied to sustained elevation (rather than a single pulse) lasts longer once it starts. That's a direct consequence of the pharmacokinetics reported by Teichman et al. ^[2], not a separate side effect profile. Ipamorelin's founding selling point, per the original Raun study, is that it avoids meaningfully raising ACTH, cortisol, or prolactin compared to other secretagogues tested in the same animal model ^[1]. If that selectivity holds in humans at research doses, ipamorelin should carry less of the cortisol-driven side effect burden (mood shifts, appetite changes, blunted immune response from sustained cortisol elevation) than older GHRPs. That's a reasonable inference from real data, but it's animal data, and human confirmation at scale is thinner than the internet's confidence about it suggests.

Which one costs more, CJC-1295 or ipamorelin?

Pricing for both compounds sits in the research-chemical gray market rather than any regulated pharmacy price list, so there's no government or insurance benchmark to cite the way there is for an FDA-approved drug. In practice, per-vial pricing for CJC-1295 (both DAC and no-DAC forms) and for ipamorelin tends to land in similar ranges from the same class of suppliers, with DAC versions sometimes priced a bit higher due to the added synthesis complexity of attaching the albumin-binding linker. Because this market has no standardized labeling, purity, or pricing oversight, cost comparisons between vendors are far less meaningful than comparing purity documentation and testing practices. If you're weighing where to source either compound, start from a provider-reviewed path rather than the cheapest listing you can find. CJC-1295 for sale and how to get CJC-1295 both cover what documentation and testing standards actually separate a defensible source from a forum flip.

CJC-1295 no-DAC vs CJC-1295 with DAC vs ipamorelin: which pulse pattern is right?

This is really three separate pharmacokinetic decisions, not one. No-DAC CJC-1295 produces a GH pulse close to what native GHRH would produce, short and sharp, decaying within roughly 30 minutes ^[2]. That mimics natural physiology more closely and is the choice if the goal is preserving a pulsatile pattern rather than flattening it into constant elevation. CJC-1295 with DAC does the opposite on purpose: it flattens the pulse into a sustained plateau lasting multiple days, per the 6-plus-day elevation window Teichman's group measured ^[2]. That's convenient for dosing frequency but is a genuinely different physiological pattern than the body's normal nightly GH pulses, and long-term consequences of sustained (versus pulsatile) GH/IGF-I elevation in healthy adults haven't been studied at scale for this specific compound. Ipamorelin sits in neither camp exactly, since it's not a GHRH analogue at all. It produces its own discrete pulse via the ghrelin receptor, with a roughly 2-hour half-life ^[3], and is generally added on top of one of the two CJC-1295 forms rather than substituted for it. If you want the full breakdown of DAC vs no-DAC mechanics and half-life data, that's covered in depth at CJC-1295 DAC or no DAC.

What does the human evidence actually show, and where does it run out?

The honest inventory is short. For CJC-1295, the main citable human data point is the Teichman et al. pharmacokinetic study in healthy adults, which established the sustained GH/IGF-I elevation profile for the DAC version ^[2]. For ipamorelin, the foundational data is Raun et al.'s animal study establishing receptor selectivity ^[1], plus scattered early pharmacology work from its original developer. Neither compound has a completed Phase 3 trial, an FDA indication, or a long-term safety study in the population most likely to be using it (healthy adults seeking performance or anti-aging effects rather than diagnosed GH deficiency). What does have real trial depth is the broader GHRH-analogue class: tesamorelin's approval for HIV lipodystrophy came out of actual controlled trials reviewed by the FDA ^[4], and it's the closest thing to a real efficacy signal for 'a GHRH analogue can meaningfully change body composition.' But tesamorelin is a distinct molecule with its own trial data; it is evidence about the class, not proof about CJC-1295 specifically. Everything past that point (optimal dosing ratios, long-term muscle gain, anti-aging claims, injection timing folklore) is protocol convention passed around forums and vendor blogs, refined by repetition rather than by controlled testing. That doesn't make it wrong. It makes it unproven, which is a different and more honest category.

Frequently asked questions

Is CJC-1295 the same thing as ipamorelin?

No. CJC-1295 is a GHRH analogue that works on the GHRH receptor; ipamorelin is a ghrelin receptor agonist (a growth hormone secretagogue) that works on an entirely different receptor. They're often used together specifically because they act through separate mechanisms, not because they're interchangeable versions of one another.

Can you take CJC-1295 without ipamorelin?

Yes, and much of the original pharmacokinetic data on CJC-1295 (Teichman et al., 2006) tested it alone, without any secretagogue paired in ^[2]. Ipamorelin is commonly added on the theory that it amplifies the GH pulse, but that's a mechanistic argument, not evidence that pairing is required for CJC-1295 to do anything.

Does ipamorelin raise cortisol like other GH peptides?

The original animal study by Raun et al. found ipamorelin did not meaningfully raise ACTH or cortisol compared to other GH secretagogues tested in the same model, which is why it's considered more 'selective' than older compounds like GHRP-6 ^[1]. Human data confirming this at scale is thinner than the animal data.

What is the difference between CJC-1295 with DAC and without DAC?

DAC (Drug Affinity Complex) is a chemical tail that lets CJC-1295 bind albumin in the blood, extending its effect from roughly 30 minutes to multiple days, based on a single human pharmacokinetic study showing sustained GH/IGF-I elevation for 6 days or more ^[2]. No-DAC CJC-1295 clears fast and is dosed more like natural GHRH pulses.

Is CJC-1295 or ipamorelin FDA approved?

Neither is FDA approved for any use. Both are sold as research chemicals in the US. The closest FDA-approved relative is tesamorelin, a different GHRH analogue approved specifically for reducing excess visceral fat in HIV-associated lipodystrophy ^[4], which is a distinct compound from CJC-1295, not an approved version of it.

How often do you inject CJC-1295 vs ipamorelin?

CJC-1295 with DAC is typically dosed weekly given its multi-day half-life; no-DAC CJC-1295 is typically dosed once or twice daily given its roughly 30-minute half-life ^[2]. Ipamorelin, with a roughly 2-hour half-life ^[3], is usually dosed once to three times daily, often around fasting periods.

Which peptide has better evidence, CJC-1295 or ipamorelin?

Neither has strong human clinical trial evidence. CJC-1295 has one notable human pharmacokinetic study ^[2]. Ipamorelin's foundational evidence is an animal receptor-selectivity study ^[1]. Both are thinner than what's expected of an approved drug, and neither has completed the kind of Phase 3 program tesamorelin went through ^[4].

Why do people combine CJC-1295 and ipamorelin instead of using one alone?

The rationale is that CJC-1295 boosts the GHRH signal that drives GH release while ipamorelin blunts somatostatin, the hormone that suppresses it, through a separate receptor. Combining a signal-booster with a brake-release is mechanistically plausible for a bigger GH pulse, but no large controlled trial has directly tested the combination against either compound alone.

Does CJC-1295 or ipamorelin cause more water retention?

Both can cause GH-axis-related water retention since that's a generic effect of elevated GH/IGF-I, not something unique to either molecule. CJC-1295 with DAC, because it sustains elevation for days rather than hours, may produce a longer-lasting version of this effect compared to ipamorelin's shorter 2-hour pulse ^[2][3].

Is ipamorelin safer than CJC-1295?

They carry different, not directly comparable, risk profiles because they act on different receptors. Ipamorelin's animal data suggests better selectivity against cortisol and prolactin release than older secretagogues ^[1]. CJC-1295's DAC version carries the added consideration of sustained multi-day hormone elevation rather than a brief pulse. Neither has a human safety database comparable to an approved drug.

How should CJC-1295 and ipamorelin be reconstituted and stored?

Both arrive as lyophilized powder and need to be reconstituted with bacteriostatic water, then refrigerated and used within a limited window to avoid degradation. Handling specifics, including recommended diluents and shelf life after mixing, are covered in detail at CJC-1295 reconstitution and CJC-1295 storage and shelf life.

Where is the best place to get CJC-1295 or ipamorelin?

Because this market is unregulated, sourcing quality varies enormously between vendors on purity, documentation, and shipping/storage handling. CJC-1295 Co reviews providers against those standards; see CJC-1295 for sale for a provider-reviewed starting point rather than picking blind from a search result.

Sources

1. Raun et al., European Journal of Endocrinology, 1998: Ipamorelin stimulates GH release selectively without significantly raising ACTH, cortisol, or prolactin in animal models.
2. Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006: A single dose of CJC-1295 with DAC produced sustained increases in GH and IGF-I for 6 days or longer in healthy adults.
3. Sigalos and Pastuszak, Sexual Medicine Reviews, 2017 (PMID 27503748): Ipamorelin's elimination half-life in humans is approximately 2 hours.
4. U.S. Food and Drug Administration, Egrifta (tesamorelin) approval label: Tesamorelin, a GHRH analogue, is FDA approved specifically for reduction of excess visceral fat in HIV-associated lipodystrophy.
5. Ionescu and Frohman, Journal of Clinical Endocrinology & Metabolism, 2006 (PMID 16787992): GHRH analogues and ghrelin-receptor-mediated growth hormone secretagogues act through distinct but complementary pathways in the somatotropic axis, providing the pharmacological basis for combining a GHRH analogue with a GH secretagogue.
6. National Library of Medicine, MedlinePlus: Growth hormone deficiency: Growth hormone and IGF-I physiology, including anabolic and metabolic effects, is documented primarily through study of growth hormone deficiency and replacement, not through studies of GH secretagogues in healthy adults.